Table 2.
AEFIs after the first dose in neurological patients and in 82 non-neurological patients paired in a 1:1 ratio according to sex, 10-year age group, number of concomitant conditions (0, 1, ≥2), and food or drug allergies.
| Parkinson’s Disease | Multiple Sclerosis | Control | |
|---|---|---|---|
| (n = 34) | (n = 48) | (n = 82) | |
| Highest grade, any AEFIs | |||
| No reactions | 25 (74%) | 16 (33%) | 26 (32%) |
| Grade I | 9 (26%) | 27 (56%) | 46 (56%) |
| Grade II | 0 (0%) | 3 (6%) | 9 (11%) |
| Grade III | 0 (0%) | 0 (0%) | 1 (1%) |
| Grade IV | 0 (0%) | 2 (4%) | 0 (0%) |
| Highest grade, local AEFIs | |||
| No reactions | 29 (85%) | 29 (60%) | 47 (57%) |
| Grade I | 5 (15%) | 15 (31%) | 32 (39%) |
| Grade II | 0 (0%) | 2 (4%) | 3 (4%) |
| Grade IV | 0 (0%) | 2 (4%) | 0 (0%) |
| Local pain | |||
| No | 29 (85%) | 30 (63%) | 48 (59%) |
| Grade I | 5 (15%) | 14 (29%) | 31 (38%) |
| Grade II | 0 (0%) | 3 (6%) | 3 (4%) |
| Grade IV | 0 (0%) | 1 (2%) | 0 (0%) |
| Local redness | |||
| No | 34 (100%) | 48 (100%) | 82 (100%) |
| Local warmth | |||
| No | 34 (100%) | 47 (98%) | 82 (100%) |
| Grade I | 0 (0%) | 1 (2%) | 0 (0%) |
| Local swelling | |||
| No | 34 (100%) | 47 (98%) | 79 (96%) |
| Grade I | 0 (0%) | 1 (2%) | 3 (4%) |
| Local itching | |||
| No | 34 (100%) | 46 (96%) | 82 (100%) |
| Grade I | 0 (0%) | 1 (2%) | 0 (0%) |
| Grade IV | 0 (0%) | 1 (2%) | 0 (0%) |
| Nodules | |||
| No | 33 (97%) | 46 (96%) | 80 (98%) |
| Grade I | 1 (3%) | 1 (2%) | 2 (2%) |
| Grade II | 0 (0%) | 1 (2%) | 0 (0%) |
| Local ecchymosis | |||
| No | 34 (100%) | 47 (98%) | 82 (100%) |
| Grade I | 0 (0%) | 1 (2%) | 0 (0%) |
| Highest grade, systemic AEFIs | |||
| No reactions | 27 (79%) | 26 (54%) | 42 (51%) |
| Grade I | 7 (21%) | 13 (27%) | 34 (41%) |
| Grade II | 0 (0%) | 8 (17%) | 5 (6%) |
| Grade III | 0 (0%) | 0 (0%) | 1 (1%) |
| Grade IV | 0 (0%) | 1 (2%) | 0 (0%) |
| Fever | |||
| No | 34 (100%) | 44 (92%) | 72 (88%) |
| Grade I | 0 (0%) | 2 (4%) | 9 (11%) |
| Grade II | 0 (0%) | 1 (2%) | 1 (1%) |
| Grade III | 0 (0%) | 1 (2%) | 0 (0%) |
| Chills | |||
| No | 34 (100%) | 36 (75%) | 70 (85%) |
| Grade I | 0 (0%) | 8 (17%) | 10 (12%) |
| Grade II | 0 (0%) | 3 (6%) | 2 (2%) |
| Grade IV | 0 (0%) | 1 (2%) | 0 (0%) |
| Joint pain | |||
| No | 32 (94%) | 40 (83%) | 65 (79%) |
| Grade I | 2 (6%) | 8 (17%) | 14 (17%) |
| Grade II | 0 (0%) | 0 (0%) | 3 (4%) |
| Muscle pain | |||
| No | 34 (100%) | 41 (85%) | 64 (78%) |
| Grade I | 0 (0%) | 6 (13%) | 14 (17%) |
| Grade II | 0 (0%) | 0 (0%) | 4 (5%) |
| Grade III | 0 (0%) | 1 (2%) | 0 (0%) |
| Malaise | |||
| No | 32 (94%) | 42 (88%) | 70 (85%) |
| Grade I | 2 (6%) | 4 (8%) | 10 (12%) |
| Grade II | 0 (0%) | 2 (4%) | 2 (2%) |
| Fatigue | |||
| No | 31 (91%) | 32 (67%) | 58 (71%) |
| Grade I | 3 (9%) | 10 (21%) | 20 (24%) |
| Grade II | 0 (0%) | 5 (10%) | 3 (4%) |
| Grade III | 0 (0%) | 1 (2%) | 1 (1%) |
| Headache | |||
| No | 32 (94%) | 43 (90%) | 60 (73%) |
| Grade I | 2 (6%) | 5 (10%) | 21 (26%) |
| Grade II | 0 (0%) | 0 (0%) | 1 (1%) |
| Nausea and/or vomiting | |||
| No | 34 (100%) | 45 (94%) | 74 (90%) |
| Grade I | 0 (0%) | 2 (4%) | 7 (9%) |
| Grade II | 0 (0%) | 0 (0%) | 1 (1%) |
| Grade III | 0 (0%) | 1 (2%) | 0 (0%) |
| Other AEFIs | |||
| No | 34 (100%) | 45 (94%) | 76 (93%) |
| Grade I | 0 (0%) | 1 (2%) | 4 (5%) |
| Grade II | 0 (0%) | 1 (2%) | 2 (2%) |
| Grade IV | 0 (0%) | 1 (2%) | 0 (0%) |